- Home
- TCRX vs HLP Comparison
TCRX vs HLP Comparison
Compare TCRX & HLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCRX | HLP |
|---|---|---|
| Founded | 2018 | 2021 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.1M | 76.4M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | TCRX | HLP |
|---|---|---|
| Price | $1.19 | $0.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 554.3K | 99.3K |
| Earning Date | 03-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | $8,423,000.00 | ★ $16,731,357.00 |
| Revenue This Year | $286.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $37.89 |
| Revenue Growth | N/A | ★ 19.13 |
| 52 Week Low | $0.88 | $0.61 |
| 52 Week High | $2.67 | $1.82 |
Technical Indicators
Market Signals| Indicator | TCRX | HLP |
|---|---|---|
| Relative Strength Index (RSI) | 57.52 | 30.43 |
| Support Level | $1.09 | $0.70 |
| Resistance Level | $1.27 | $0.85 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 70.81 | 30.51 |
Price Performance
Historical ComparisonAbout TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.